Similar to prior studies, the three most frequent mutations include TET2, ASXL1 and SRSF2. 1, 2 Unlike in MDS, survival outcomes in CMML were not affected by the number of concurrent driver mutations. This evidence concerns the gene ASXL1 and chronic myelomonocytic leukemia.